CASP9 and inflammatory bowel disease: Caspase 9 concentration tended to be lower also in IBD patients treated with AZA (2.98 ng/ml (1.23-7.21) vs. 10.9 ng/ml 3.48-34.3), p=0.057) or CS (2.46 ng/ml (1.02-5.93) vs. 7.96 ng/ml (2.95-21.5), p=0.093).